Exploratory Clinical Study of the Combination of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Gastric cancer; Liver cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 22 Oct 2018 Results (data cut off: 15 Jun, 2018; n=43) published in the Clinical Cancer Research.
- 18 Jun 2018 New trial record
- 05 Jun 2018 Results (n=42 data cut off: Feb 2, 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology